Acta Dermato-Venereologica Suppl 219 AbstractPsoriasis2018 | Page 60

58

5 th World Psoriasis & Psoriatic Arthritis Conference 2018

ments in work productivity and reductions in activity impairment were seen with both CZP doses vs PBO; and were maintained to Week 48 in patients remaining in the trial.( Table). Conclusions: Treatment with CZP was associated with improvements in QoL, work productivity and social activities vs PBO at Week 16, which was maintained to Week 48 in patients remaining in the trials.

Table. Improvements in DLQI and WPAI at Weeks 16 and 48

[ n = 89 ]-21.0( 31.9)-23.9( 29.4)

[ n = 132 ]

P142 TRANSLATING WHO RESOLUTION INTO THE PUBLIC: THE GERMAN PROGRAM AGAINST STIGMATIZATION

OF PEOPLE WITH CHRONIC VISIBLE SKIN DISEASES Matthias Augustin 1, Claudia Luck-Sikorski 2, Rachel Sommer 1, Janine Topp 1, Ines Schaefer 1, Marc Radtke 1, Sophie Schlette 3, Natascha Weinberger 4, Regina Spreckelsen 5, Anja Hilbert 6, Alexander Zink 7, Dagmar Wilsmann-Theis 8, Eckardt Breitbart 9, Ulrich Mrowietz 10 1

University Medical Center Hamburg-Eppendorf, 2 University Gera,

3

BVDD, 4 University of Leipzig, 5 University Hospital Kiel, 6 University Medical Center Leipzig, 7 University Munich, 8 University Bonn, 9 Dermatology Breitbart, 10 University Kiel

Introduction: The WHO resolution 2014 raised fundamental demands for the health care system to increase the awareness for patients with chronic skin diseases such as psoriasis, including its fight against stigmatization. Single member states were encouraged to take action on all levels, including public awareness campaigns. After a period of refusal, the German ministry of health approved a project submitted by German dermatologists, patient groups and further experts to develop interventions against stigmatization. Objectives- Aim of investigation: The project aims to develop and evaluate public interventions against stigmatization of people with visible skin diseases. Methods: The project consist of three phases. Within a one-year period current research will be processed through a systematic literature search; recommendations for intervention formats will be derived. The consecutive 18 months involve the development of defined intervention formats. The interventions are supposed to focus on locations of stigma and encounters of stigmatizing with stigmatized persons. Results: The application has been approved and is funded by the German ministry of health for a period of three years throughout the years 2018 to 2021. The project group consists of 25 dermatology-, science- and patient-experts who work in operative groups in order to develop the content and the intervention format. In doing so, different levels of the stigmatization process, namely stereotypes, prejudice, discrimination are considered as important aspects and will be accounted for in the development of the intervention. First results of the literature review imply that people with visible skin disease such as psoriasis are affected by stigmatization in several dimensions and strategies for reducing the stigma are required. Conclusion: Following the WHO resolution, this project is an example for successful project initiation of an interdisciplinary team to develop and implement an intervention against stigmatization.

First outcomes will be a comprehensive review of papers derived from the systematic literature search in May 2018.

P143 THE GLOBAL RESEARCH ON THE IMPACT OF

DERMATOLOGICAL DISEASES( GRIDD) Matthias Augustin 1, Nirohshah Suthakharan 1, Christine Janus 2, Jennifer Austin 2, Christine Bundy 3, Rachael Pattinson 3

1

University Medical Center Hamburg, Institute for Health Services Research in Dermatology and Nursing( IVDP), 2 International Alliance of Dermatology Patient Organisations – IADPO, 3 University of Cardiff

Introduction: The Global Research on the Impact of Dermatological Diseases( GRIDD) project will be the first global patientinitiated and patient-led impact research study in dermatology. By including the patient perspective stringently into the burden metrics, this will be the first program to systematically challenge the current Global Burden of Disease concept, which markedly underestimates the patient burden of skin diseases. Objective: The objective of the GRIDD research project is to develop a comprehensive measure of the impact of living with skin diseases instruments by country, regionally and worldwide. The global instrument, developed with patient organisations, will capture patient experiences, including the extent of disease impact and burden for patients and their families, for generic( i. e. all dermatological diseases) and specific dermatological disease including psoriasis assessment worldwide. Materials + Methods: Development of the comprehensive measure of impact of disease will be based on a novel methodology with several phases. Phase 1 will systematically review existing measures of the life impact of skin diseases and conduct a patientcentered item identification exercise. Phase 2 will be informed by Phase 1 data and will focus on instrument development: develop the wording for items( i. e. impact categories) and appropriate item scaling. This measure will describe the impact on life which may include economic; psychological and social impacts. Phase 3 describes the acquisition of real world data to further test the validity and acceptability of the new measure. Lastly, phase 4 and 5 include dissemination and launch of data, the new measure and an implementation strategy to increase uptake of the measure. Results: GRIDD has assembled a scientific advisory board representing different regions worldwide. Currently, we are collaborating with over 100 patient associations in 32 countries worldwide, with more than 26 disease areas. Industry funding has been secured from five different companies for the first phase and a portion of phase 2. The GRIDD research team, including researcher from the University Medical Center in Hamburg and University of Cardiff, met in 2017 to start phases 1 and 2. The systematic literature review on“ Existing patient-centred outcome measures currently used in dermatology” is currently underway. Conclusion: This novel patient-centric methodology will complement existing concepts of evaluating patient perspective in dermatology. GRIDD will provide an extended patient view for better decision making in dermatology on a global and country level. It supports local, regional and international attempts to create awareness, better position psoriasis and other skin diseases and encourage decision-makers and stakeholders to include dermatological diseases in their policies.

P144 TREATMENT OF NAIL PSORIASIS WITH DIFFE RENT

PULSE DURATIONS OF PULSED DYE LASER Mohamad Goldust 1, Homan Alipour 2

1

Mazandaran University of Medical Sciences, 2 Tabriz University of Medical Sciences

Background: There are different treatment modalities for nail psoriasis but the treatment of choice is still controversial. Laser www. medicaljournals. se / acta